Biosimilar Substitution Could Rely On Electronic Medical Records
Executive Summary
Pharmacy notification of physicians about substitution of interchangeable biosimilars is floated by a group of brand and generic firms, but opponents of the proposal suggest it is being pushed by companies that plan to use sales forces to market their biosimilars.